UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of August, 2022
COMMISSION FILE NUMBER 001-38455
MorphoSys AG
Semmelweisstrasse 7
82152 Planegg
Germany
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F: Form 20-F x Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨
On August 3, 2022, MorphoSys AG (the “Company”) issued a press release with the second quarter and first half 2022 financial results attached hereto as Exhibit 99.1. On August 4, 2022, MorphoSys AG (the “Company”), held its Q2 2022 results conference call attached hereto as Exhibit 99.2.
Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
MORPHOSYS AG (Registrant)
Date: August 4, 2022 By: /s/ i.A. Kristina Grötsch
Name: Kristina Grötsch
Title: Senior Specialist Investor Relations
By: /s/ i.A. Robert Mayer
Name: Dr. Robert Mayer
Title: Director Investor Relations